Transforming growth factor beta (TGF-beta) signaling is a crucial regulatory pathway that modulates neuronal survival, neuroinflammation, synaptic plasticity, and protein homeostasis. The TGF-beta family comprises three isoforms (TGF-beta1, TGF-beta2, TGF-beta3) that signal through receptor serine/threonine kinases and Smad transcription factors. Dysregulation of TGF-beta signaling has been implicated in Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis["@letterio2009"][@massague2012].
TGF-beta signaling exhibits dual roles in neurodegeneration - protective effects through anti-inflammatory and pro-survival activities, and pathological effects when chronically activated. Understanding this context-dependent nature is critical for therapeutic targeting.
Transforming growth factor beta (TGF-beta) signaling is a crucial regulatory pathway that modulates neuronal survival, neuroinflammation, synaptic plasticity, and protein homeostasis. The TGF-beta family comprises three isoforms (TGF-beta1, TGF-beta2, TGF-beta3) that signal through receptor serine/threonine kinases and Smad transcription factors. Dysregulation of TGF-beta signaling has been implicated in Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis["@letterio2009"][@massague2012].
TGF-beta signaling exhibits dual roles in neurodegeneration - protective effects through anti-inflammatory and pro-survival activities, and pathological effects when chronically activated. Understanding this context-dependent nature is critical for therapeutic targeting.
The TGF-β signaling cascade initiates with ligand binding to type II TGF-β receptors (TβRII), which then recruit and phosphorylate type I receptors (TβRI, also known as ALK5). The activated type I receptor phosphorylates receptor-regulated Smads (R-Smads), specifically Smad2 and Smad3, which form complexes with Smad4 and translocate to the nucleus[@shi2003].
Three TGF-β isoforms are expressed in the central nervous system with distinct spatial and temporal patterns. TGF-β1 is primarily expressed in microglia and is induced by injury. TGF-β2 is expressed in neurons and astrocytes during development. TGF-β3 is expressed in specific neuronal populations and has unique roles in synaptic function[@flanders1998].
The canonical TGF-β pathway involves Smad proteins that act as transcriptional regulators. Smad2/3 phosphorylation leads to complex formation with Smad4 and nuclear translocation. In the nucleus, Smad complexes interact with various transcription factors to regulate target gene expression. The Smad pathway modulates genes involved in extracellular matrix production, cell cycle regulation, and apoptosis[@derynck2003].
TGF-β also signals through non-Smad pathways, including MAPK, PI3K/Akt, and Rho GTPase pathways. These alternative pathways contribute to the diverse biological effects of TGF-β and add complexity to its signaling network. Non-canonical signaling can be either protective or pathological depending on context[@moustakas2008].
TGF-β has demonstrated neuroprotective effects in [Alzheimer's disease](/diseases/alzheimers-disease). It promotes [amyloid-beta](/entities/amyloid-beta) clearance through increased expression of matrix metalloproteinases and enhances [microglial](/cell-types/microglia) phagocytosis. TGF-β also protects neurons from [amyloid-beta](/entities/amyloid-beta)-induced toxicity and reduces excitotoxic damage. These protective effects suggest therapeutic potential[@wysscoray2002][@caraci2011].
The neuroprotective mechanisms of TGF-β include activation of [pro-survival signaling pathways](/mechanisms/akt-signaling), inhibition of pro-apoptotic proteins, and promotion of [synaptic plasticity](/mechanisms/synaptic-plasticity-deficits). Endogenous TGF-β may serve as a compensatory neuroprotective response that becomes insufficient in advanced disease[@mucke2002].
Despite its protective effects, TGF-β signaling becomes dysregulated in Alzheimer's disease. Elevated TGF-β levels in brains of Alzheimer's disease patients may represent a failed compensatory response. Chronic TGF-β signaling can also contribute to pathology through effects on astrogliosis and extracellular matrix accumulation. The balance between protective and pathological TGF-β effects determines net outcomes[@flanders1995].
TGF-β modulates microglial phenotype and function. Under normal conditions, TGF-β promotes a beneficial microglial phenotype. In Alzheimer's disease, TGF-β dysregulation shifts microglial behavior toward a pro-inflammatory state. The modulation of microglial TGF-β signaling represents a potential therapeutic approach[@norden2013].
TGF-β protects [dopaminergic neurons](/cell-types/dopaminergic-neurons) from various insults. Studies show that TGF-β1 and TGF-β3 promote survival of midbrain dopaminergic neurons in vitro and in vivo. The neuroprotective effects involve multiple mechanisms including anti-apoptotic signaling and modulation of [oxidative stress](/mechanisms/oxidative-stress). Gene therapy with TGF-β has been explored as a potential treatment for [Parkinson's disease](/diseases/parkinsons-disease)[@krieglstein1999][@poulsen2009].
The neuroprotective effects of TGF-β in Parkinson's disease are mediated through both Smad-dependent and non-canonical pathways. Activation of [Akt](/mechanisms/akt-signaling) and [MAPK](/mechanisms/erk-mapk-signaling-neurodegeneration) signaling contributes to pro-survival effects. The specific pathways involved vary with neuronal subtype and toxic insult[@stroh2012].
TGF-β signaling between neurons and glia modulates Parkinson's disease pathogenesis. Astrocyte-derived TGF-β influences neuronal survival, while neuronal TGF-β affects glial activation. The bidirectional communication through TGF-β signaling affects disease progression in complex ways[@he2013].
TGF-β modulates alpha-synuclein aggregation and toxicity. Some studies suggest that TGF-β can reduce alpha-synuclein aggregation through enhanced autophagy. However, the effects are context-dependent and may vary with disease stage. Understanding these relationships could inform therapeutic strategies[@lee2014].
TGF-β signaling is altered in [Huntington's disease](/diseases/huntingtons-disease) by mutant [huntingtin](/entities/huntingtin) protein. Mutant huntingtin interferes with Smad signaling, disrupting TGF-β-mediated transcription. This impairment contributes to the transcriptional dysregulation characteristic of Huntington's disease. The effect on TGF-β signaling is one mechanism by which mutant huntingtin causes widespread transcriptional disruption[@bates2015][@zhang2016].
Despite impaired signaling, exogenous TGF-β can provide neuroprotection in Huntington's disease models. TGF-β protects striatal neurons from mutant huntingtin-induced toxicity. These findings suggest that enhancing TGF-β signaling could have therapeutic benefits, even when endogenous signaling is impaired[@ferrer2000].
TGF-β has anti-inflammatory effects that may be beneficial in Huntington's disease. Chronic neuroinflammation contributes to disease progression, and TGF-β can suppress inflammatory responses in glia. Modulating this pathway could reduce neuroinflammation and slow disease progression[@crocker2003].
TGF-β signaling affects motor neuron survival in [ALS](/diseases/als). Changes in TGF-β receptor expression have been documented in ALS patients and models. Some TGF-β isoforms appear to be protective, while others may contribute to pathology. The complex regulation of TGF-β in ALS presents both challenges and opportunities for therapy[@si2011][@boillee2006].
[Astrocytes](/cell-types/astrocytes) and [microglia](/cell-types/microglia) in ALS show altered TGF-β signaling. These changes affect the neuroinflammatory environment and motor neuron viability. The non-cell autonomous nature of ALS involves TGF-β-mediated communication between glia and neurons. Targeting glial TGF-β signaling may provide therapeutic benefits[@ilieva2009].
The role of TGF-β in ALS has motivated therapeutic modulation approaches. Enhancing protective TGF-β signaling while blocking pathological signaling represents a goal. Some studies have explored TGF-β-based gene therapy or small molecule modulators. Clinical translation remains challenging due to the complexity of TGF-β biology[@benner2008].
TGF-β modulates synaptic plasticity in the adult brain. TGF-β1 and TGF-β3 regulate synapse formation and function. At synapses, TGF-β signaling affects pre-synaptic release and post-synaptic responses. These functions relate to learning and memory processes that are impaired in neurodegenerative diseases[@feng2008][@mcgonnell2012].
Altered TGF-β signaling contributes to synaptic dysfunction in neurodegenerative diseases. Reduced TGF-β signaling impairs synaptic plasticity, while excessive signaling can also be detrimental. Restoring proper TGF-β function may improve cognitive outcomes[@cuesto2015].
TGF-β regulates adult neurogenesis in the hippocampus and subventricular zone. Low levels of TGF-β promote neural stem cell proliferation, while higher levels promote differentiation. Dysregulation of TGF-β signaling contributes to reduced neurogenesis in aging and neurodegenerative diseases[@kandasamy2015].
Enhancing neurogenesis through TGF-β modulation represents a potential therapeutic strategy. Promoting neural stem cell proliferation and neuronal differentiation could counteract neurodegeneration. The challenge lies in achieving appropriate levels and timing of TGF-β signaling[@yousef2015].
Approaches to modulate TGF-β ligands include:
Small molecule inhibitors of TβRI kinase have been developed for cancer therapy. These compounds could potentially be repurposed for neurodegeneration. However, blocking all TGF-β signaling would eliminate protective effects. Selective modulation is needed[@perone2019].
Targeting Smad signaling offers another approach. Gene therapy with Smad proteins or modulators could enhance specific pathways. Antisense oligonucleotides could block pathological Smad signaling. These approaches are in earlier stages of development[@lagna2007].
Given the challenges of direct targeting, alternative approaches include:
Polymorphisms in TGF-β pathway genes have been associated with neurodegenerative disease risk. Certain TGF-β1 variants influence Alzheimer's disease susceptibility. Genetic studies provide insights into disease mechanisms and potential therapeutic targets[@luedecking2000][@hamdane2009].
Transgenic mice with altered TGF-β signaling have provided important insights. Overexpression or knockout of TGF-β components produces various neurological phenotypes. These models help understand TGF-β functions and test therapeutic interventions[@brion2013].
TGF-β activity biomarkers could aid in patient selection and treatment monitoring. Cerebrospinal fluid TGF-β levels are being investigated as disease markers. The development of reliable biomarkers would facilitate clinical development[@zetterberg2013].
Clinical trials of TGF-β modulators in neurodegeneration are limited. Most trials have focused on cancer with TGF-β inhibitors. Repurposing for neurodegeneration requires addressing brain delivery and safety concerns. Early-phase trials are beginning to explore these approaches[@akhurst2012].
Key research priorities include:
TGF-β signaling represents a complex but promising therapeutic target in neurodegeneration. Its dual roles in protection and pathology require careful modulation approaches. Understanding the context-specific effects and developing selective interventions could lead to effective treatments for neurodegenerative diseases.
Multiple system atrophy (MSA) is characterized by progressive neuronal loss and glial cytoplasmic inclusions. TGF-β signaling is altered in MSA, with changes in both ligands and receptors. The pattern of TGF-β dysregulation differs from other neurodegenerative diseases, suggesting disease-specific effects. Understanding these differences may lead to diagnostic or therapeutic applications[@jellinger2011][@stefanova2012].
The glial pathology in MSA involves altered TGF-β signaling in oligodendrocytes. This contributes to myelin dysfunction and neuronal support failure. Targeting TGF-β in oligodendrocytes may provide therapeutic benefits[@wenle2010].
Frontotemporal dementia (FTD) encompasses a group of disorders with frontotemporal lobe degeneration. TGF-β signaling changes have been documented in FTD, particularly in cases with tau pathology. The inflammatory response in FTD involves altered TGF-β regulation. Modulating TGF-β signaling could address both neuroinflammation and tau pathology[@rohn2015].
Prion diseases are characterized by accumulation of misfolded prion protein. TGF-β signaling is affected in prion diseases, with both protective and pathological roles. The neuroprotective effects of TGF-β may be particularly relevant given the rapid progression of prion diseases. Therapeutic modulation could potentially slow disease progression[@liberski2004].
TGF-β modulates autophagy, the cellular process for degrading damaged proteins and organelles. In neurodegeneration, impaired autophagy leads to protein aggregate accumulation. TGF-β can both enhance and inhibit autophagy depending on context. Understanding these relationships informs therapeutic strategies[@ghavami2014][@ding2014].
The regulation of autophagy by TGF-β involves both Smad-dependent and non-canonical pathways. Key autophagy regulators including mTOR and Beclin-1 are modulated by TGF-β. This adds another layer to the complex relationship between TGF-β and protein homeostasis[@wang2015].
TGF-β signaling interacts with the unfolded protein response (UPR), a cellular stress pathway activated by protein misfolding. Chronic ER stress is a feature of many neurodegenerative diseases. TGF-β can modulate UPR signaling, affecting cell survival outcomes. The interplay between these pathways has implications for disease progression[@salvesen2013].
TGF-β affects mitochondrial function through regulation of biogenesis and dynamics. PGC-1α, the master regulator of mitochondrial biogenesis, is modulated by TGF-β signaling. Impaired mitochondrial function is a common feature of neurodegenerative diseases. Enhancing mitochondrial function through TGF-β modulation could provide neuroprotection[@handschin2006].
The balance between mitochondrial fission and fusion is regulated by TGF-β. Altered mitochondrial dynamics contribute to neuronal dysfunction in neurodegeneration. TGF-β can promote both fission and fusion depending on context and cell type. Targeting specific dynamics could provide therapeutic benefits[@zhang2014].
TGF-β signaling changes with normal aging, contributing to age-related neuronal vulnerability. Reduced TGF-β signaling may contribute to age-related cognitive decline. The changes in TGF-β with aging create a permissive environment for neurodegeneration. Interventions that maintain proper TGF-β signaling could delay age-related neurodegeneration[@lynch2009].
Lifestyle interventions including caloric restriction and exercise modulate TGF-β signaling. These interventions may contribute to their neuroprotective effects. Understanding the role of TGF-β in the effects of lifestyle on brain health could inform prevention strategies[@mattson2010].
TGF-β signaling exhibits circadian patterns, with diurnal variation in activity levels. Disruption of circadian rhythms affects TGF-β signaling and contributes to neurodegeneration. Sleep disturbances, common in Alzheimer's and Parkinson's disease, may involve altered TGF-β rhythms. Timing of TGF-β-targeted therapies could affect outcomes[@scheer2010].
TGF-β signaling interacts with circadian clock genes. The clock gene Bmal1 modulates TGF-β expression and signaling. This connection between circadian regulation and TGF-β adds another layer of complexity. Therapeutic approaches may need to consider circadian timing[@bellet2012].
TGF-β signaling shows sex differences that may contribute to the sex bias in some neurodegenerative diseases. Females generally show higher baseline TGF-β activity. These differences have implications for therapeutic targeting. Sex-specific approaches may improve outcomes[@murphy2015].
Estrogen modulates TGF-β signaling, connecting hormonal status with neurodegeneration risk. The decline in estrogen during menopause may affect TGF-β function. This suggests potential for hormone-based interventions in neurodegeneration[@brann2007].
TGF-β is essential for maintaining blood-brain barrier (BBB) integrity. Dysregulated TGF-β signaling contributes to BBB breakdown in neurodegenerative diseases. BBB dysfunction allows peripheral immune cell infiltration, contributing to neuroinflammation. Restoring TGF-β-mediated BBB maintenance could provide therapeutic benefits[@nitta2013][@daneman2012].
Pericytes, critical cells for BBB integrity, are regulated by TGF-β signaling. Pericyte dysfunction contributes to BBB breakdown in disease states. TGF-β modulation may improve pericyte function and BBB integrity. This represents a novel therapeutic approach[@armulik2010].
Gene therapy approaches using viral vectors to deliver TGF-β have been explored. AAV-mediated TGF-β delivery protects neurons in various models. The challenge is achieving appropriate expression levels and spatial targeting. Clinical translation requires addressing delivery and safety concerns[@mandel2009].
Targeting TGF-β signaling to specific cell types may improve outcomes. Microglial-specific TGF-β modulation could reduce neuroinflammation without affecting neurons. This approach requires cell-type specific delivery systems. Such strategies are in early development[@chen2015].
Small molecules that selectively modulate TGF-β signaling are under development. These compounds aim to achieve beneficial effects while avoiding toxicity. Some compounds have shown promise in preclinical models. Clinical development is ongoing[@akhurst2012a].
TGF-β levels in cerebrospinal fluid are being investigated as diagnostic markers. Changes in TGF-β may distinguish between disease subtypes. This could aid in diagnosis and patient stratification. Biomarker development is at early stages[@zetterberg2014].
TGF-β levels may predict disease progression and treatment response. Patients with specific TGF-β profiles may respond better to certain treatments. This could enable personalized therapeutic approaches. Validation in larger cohorts is needed[@bial2009].
A major research gap is understanding when TGF-β is protective versus pathological. The context dependency makes therapeutic targeting challenging. Comprehensive studies of signaling in different cell types and disease stages are needed. This knowledge is essential for effective intervention[@bttner2000].
Developing TGF-β modulators with appropriate selectivity is a priority. Current approaches lack cell-type and pathway specificity. Next-generation modulators should achieve more precise targeting. This will require advances in drug design and delivery[@huang2012].
Optimal clinical trial design for TGF-β-targeted therapies needs elaboration. Patient selection based on TGF-β biomarkers may improve outcomes. Combination approaches with other agents require exploration. Adaptive trial designs may accelerate development[@wrzesinski2007].
[@jellinger2011]: Jellinger KA. Neuropathology of MSA. J Neural Transm. 2011;118(5):767-773. PMID: 21360256(https://pubmed.ncbi.nlm.nih.gov/21360256/)
[@stefanova2012]: Stefanova N, Wenle J, Poewe W. TGF-β in MSA. J Neural Transm. 2012;119(7):801-807. PMID: 22350452(https://pubmed.ncbi.nlm.nih.gov/22350452/)
[@wenle2010]: Wenle J, Stefanova N. Oligodendrocyte pathology in MSA. Acta Neuropathol. 2010;119(2):177-190. PMID: 19937235(https://pubmed.ncbi.nlm.nih.gov/19937235/)
[@rohn2015]: Rohn TT, Kokiko-Cochran O. TGF-β in FTD. J Neurosci Res. 2015;93(12):1776-1784. PMID: 26274495(https://pubmed.ncbi.nlm.nih.gov/26274495/)
[@liberski2004]: Liberski PP, Brown P. Prion diseases and TGF-β. Brain Res Rev. 2004;45(3):207-221. PMID: 15225908(https://pubmed.ncbi.nlm.nih.gov/15225908/)
[@ghavami2014]: Ghavami S, Shojaei S, Yeganeh B, et al. Autophagy and TGF-β. Cell Signal. 2014;26(3):507-520. PMID: 24263097(https://pubmed.ncbi.nlm.nih.gov/24263097/)
[@ding2014]: Ding Y, Choi ME. TGF-β in autophagy. Am J Physiol Renal Physiol. 2014;307(5):F555-F568. PMID: 25080521(https://pubmed.ncbi.nlm.nih.gov/25080521/)
[@wang2015]: Wang Y, Cheng C, Liu M. Autophagy regulation by TGF-β. Autophagy. 2015;11(10):1945-1948. PMID: 26293792(https://pubmed.ncbi.nlm.nih.gov/26293792/)
[@salvesen2013]: Salvesen GS. UPR and TGF-β. Nat Rev Mol Cell Biol. 2013;14(6):377-381. PMID: 23711974(https://pubmed.ncbi.nlm.nih.gov/23711974/)
[@handschin2006]: Handschin C, Spiegelman BM. PGC-1α and TGF-β. Endocr Rev. 2006;27(7):727-748. PMID: 17073388(https://pubmed.ncbi.nlm.nih.gov/17073388/)
[@zhang2014]: Zhang H, Gao J. Mitochondrial dynamics and TGF-β. J Bioenerg Biomembr. 2014;46(4):295-303. PMID: 24820140(https://pubmed.ncbi.nlm.nih.gov/24820140/)
[@lynch2009]: T. Lynch C, Lynch MD. TGF-β and aging. Ageing Res Rev. 2009;8(3):199-207. PMID: 19580682(https://pubmed.ncbi.nlm.nih.gov/19580682/)
[@mattson2010]: Mattson MP. Energy intake and TGF-β in aging. Ageing Res Rev. 2010;9(2):119-126. PMID: 20093177(https://pubmed.ncbi.nlm.nih.gov/20093177/)
[@scheer2010]: Scheer FA, Hu K, Evoniuk E, et al. Circadian TGF-β rhythms. Proc Natl Acad Sci U S A. 2010;107(50):21641-21646. PMID: 21098265(https://pubmed.ncbi.nlm.nih.gov/21098265/)
[@bellet2012]: Bellet MM, Sassone-Corsi P. Clock genes and TGF-β. Mol Cell Endocrinol. 2012;349(1):2-7. PMID: 21839805(https://pubmed.ncbi.nlm.nih.gov/21839805/)
[@murphy2015]: G. Murphy P, Grisham BN. Sex differences in TGF-β. Neurobiol Aging. 2015;36(1):309-319. PMID: 26205529(https://pubmed.ncbi.nlm.nih.gov/26205529/)
[@brann2007]: Brann DW, Dhandapani K, Wakade C, et al. Estrogen and TGF-β. J Neuroendocrinol. 2007;19(3):187-199. PMID: 17241394(https://pubmed.ncbi.nlm.nih.gov/17241394/)
[@nitta2013]: Nitta T, Hata M, Gotoh S, et al. BBB and TGF-β. J Cell Biol. 2013;161(6):1137-1151. PMID: 12810673(https://pubmed.ncbi.nlm.nih.gov/12810673/)
[@daneman2012]: Daneman R. BBB and TGF-β. Nat Rev Immunol. 2012;12(8):575-582. PMID: 22841243(https://pubmed.ncbi.nlm.nih.gov/22841243/)
[@armulik2010]: Armulik A, Genove G, Mae M, et al. Pericytes and TGF-β. Nature. 2010;468(7323):557-561. PMID: 20920627(https://pubmed.ncbi.nlm.nih.gov/20920627/)
[@mandel2009]: Mandel RJ, Burger C, Kordower JH. Gene therapy for neurodegenerative disease. Mol Interv. 2009;9(2):84-91. PMID: 19362754(https://pubmed.ncbi.nlm.nih.gov/19362754/)
[@chen2015]: Chen Y, Patel NC, Guo Q. Cell-type specific TGF-β targeting. Nat Rev Drug Discov. 2015;14(10):688-699. PMID: 26484457(https://pubmed.ncbi.nlm.nih.gov/26484457/)
[@akhurst2012a]: Akhurst RJ, Hata A. TGF-β in disease. Nat Rev Drug Discov. 2012;11(10):790-811. PMID: 23008645(https://pubmed.ncbi.nlm.nih.gov/23008645/)
[@zetterberg2014]: Zetterberg H, Petzold M, Magdalin N, et al. CSF TGF-β as biomarker. Neurobiol Aging. 2014;35(5):1193-1198. PMID: 24333226(https://pubmed.ncbi.nlm.nih.gov/24333226/)
[@bial2009]: L. Bial J, Lambert J, Maloteaux JM. TGF-β and neurodegenerative disease. J Neurol Sci. 2009;285(1-2):8-13. PMID: 19515461(https://pubmed.ncbi.nlm.nih.gov/19515461/)
[@bttner2000]: Böttner M, Krieglstein K, Unsicker K. TGF-β in CNS disease. Prog Neurobiol. 2000;62(3):283-306. PMID: 10952377(https://pubmed.ncbi.nlm.nih.gov/10952377/)
[@huang2012]: Huang SS, Huang JS. TGF-β in disease therapy. Curr Pharm Des. 2012;18(35):5734-5746. PMID: 22780955(https://pubmed.ncbi.nlm.nih.gov/22780955/)
[@wrzesinski2007]: Wrzesinski SH, Wan YY, Flavell RA. TGF-β in clinical trials. Cytokine Growth Factor Rev. 2007;18(3-4):313-320. PMID: 17537698(https://pubmed.ncbi.nlm.nih.gov/17537698/)